# US 2020/0390734 A1 · Nutraceutical formulation for unblocking receptors

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0390734 A1
- Document ID: US20200390734A1
- Status: Published application
- Kind: A1
- Application number: 16/897,475
- Filed: 2020-06-10
- Published: 2020-12-17
- Earliest claimed: 2019-06-11
- Assignees: Dremcubed, LLC
- Applicants: Dremcubed, LLC
- Inventors: Amy Motil; Matt Motil
- Web page: https://patentgrep.com/patent/US20200390734A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A23L 29/04: {Fatty acids or derivatives}
- A23L 33/105: Plant extracts, their artificial duplicates or their derivatives
- A23L 33/115: Fatty acids or derivatives thereof; Fats or oils
- A23L 33/12: Fatty acids or derivatives thereof
- A23L 33/135: Bacteria or derivatives thereof, e.g. probiotics
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 31/352: condensed with carbocyclic rings, e.g. methantheline {(cannabinoids A61K31/658)}
- A61K 35/741: Probiotics (probiotic yeast, e.g. saccharomyces A61K36/06)
- A61K 35/744: Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K 35/747: Lactobacilli, e.g. L. acidophilus or L. brevis
- A61K 36/28: Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A23V 2002/00: Food compositions, function of food ingredients or processes for food or foodstuffs
- A23V 2400/113: Acidophilus
- A23V 2400/249: Thermophilus
- A61K 2035/115: {Probiotics}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A23L: FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF (preservation thereof A23B)
- A23V: INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION

## Abstract

A nutraceutical formulation used to unblock receptors is disclosed herein. The nutraceutical formulation used to therapeutically treat humans includes arachidonic acid, docosahexaenoic acid (DHA), echinacea, kaempferol, coffee fruit, and probiotics.

## Claims

### Claim 1

A nutraceutical formulation, comprising:
arachidonic acid;
docosahexaenoic acid;
echinacea;
kaempferol; and
at least one probiotic.

### Claim 2 (depends on 1)

The nutraceutical formulation of claim 1, further comprising coffee fruit.

### Claim 3 (depends on 1)

The nutraceutical formulation of claim 1, the arachidonic acid is present in a concentration ranging from about 30 percent to about 60 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 4 (depends on 1)

The nutraceutical formulation of claim 1, wherein the arachidonic acid is present in a concentration of about 46 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 5 (depends on 1)

The nutraceutical formulation of claim 1, wherein the docosahexaenoic is present in a concentration ranging from about 15 percent to about 30 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 6 (depends on 1)

The nutraceutical formulation of claim 1, wherein the docosahexaenoic acid is present in a concentration of about 19 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 7 (depends on 1)

The nutraceutical formulation of claim 1, wherein the echinacea is present in a concentration ranging from about 1 percent to about 5 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 8 (depends on 1)

The nutraceutical formulation of claim 1, wherein the echinacea is present in a concentration of about 2 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 9 (depends on 1)

The nutraceutical formulation of claim 1, wherein the kaempferol is present in a concentration ranging from about 20 percent to about 40 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 10 (depends on 1)

The nutraceutical formulation of claim 1, wherein the kaempferol is present in a concentration of about 33 percent, by weight relative to a total weight of the nutraceutical formulation less a weight of the at least one probiotic.

### Claim 11 (depends on 1)

The nutraceutical formulation of claim 1, wherein the at least one probiotic is present in an amount of about 1×109 CFU/g.

### Claim 12 (depends on 1)

The nutraceutical formulation of claim 1, wherein the at least one probiotic includes one of Lactobacillus acidophilus and Streptococcus thermopholis.

### Claim 13 (depends on 12)

The nutraceutical formulation of claim 12, wherein the at least one probiotic is a combination of Lactobacillus acidophilus and Streptococcus thermopholis.

### Claim 14 (depends on 1)

The nutraceutical formulation of claim 1, further comprising at least one aromatic spice.

### Claim 15 (depends on 14)

The nutraceutical formulation of claim 14, wherein the at least one aromatic spice is one of oregano or cinnamon.

### Claim 16 (depends on 1)

The nutraceutical formulation of claim 1, wherein the formulation is provided in a dosage form suitable for oral administration.

### Claim 17 (depends on 16)

The nutraceutical formulation of claim 16, wherein the dosage form is a tablet or a capsule.

### Claim 18 (depends on 1)

The nutraceutical formulation of claim 1, further comprising at least one excipient.

### Claim 19

A nutraceutical formulation, consisting essentially of:
arachidonic acid;
docosahexaenoic acid;
echinacea;
kaempferol; and
a probiotic.

### Claim 20

A nutraceutical formulation, consisting of:
arachidonic acid;
docosahexaenoic acid;
echinacea;
kaempferol; and
a probiotic.
